Keystone Financial Planning Inc. Purchases New Stake in Medtronic PLC $MDT

Posted by Francis Steltz on Sep 10th, 2026

Keystone Financial Planning Inc. purchased a new stake in shares of Medtronic PLC (NYSE:MDT – Free Report) in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 126,411 shares of the medical technology company’s stock, valued at approximately $9,889,000. Medtronic comprises about 2.5% of Keystone Financial Planning Inc.’s investment portfolio, making the stock its 9th biggest position.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Monetary Solutions Ltd bought a new position in shares of Medtronic in the fourth quarter valued at about $27,000. Acumen Wealth Advisors LLC acquired a new stake in shares of Medtronic during the 4th quarter worth about $29,000. IAG Wealth Partners LLC bought a new stake in shares of Medtronic during the 2nd quarter worth about $30,000. Imprint Wealth LLC bought a new stake in shares of Medtronic during the 3rd quarter worth about $31,000. Finally, Basepoint Wealth LLC acquired a new position in Medtronic in the 4th quarter valued at about $32,000. 82.06% of the stock is owned by institutional investors.

Analyst Ratings Changes

MDT has been the topic of several research analyst reports. TD Cowen increased their price target on shares of Medtronic from $100.00 to $110.00 and gave the company a “buy” rating in a report on Friday, August 28th. The Goldman Sachs Group decreased their target price on Medtronic from $84.00 to $83.00 and set a “neutral” rating on the stock in a research report on Thursday, June 4th. Royal Bank Of Canada reiterated an “outperform” rating and set a $118.00 target price on shares of Medtronic in a research note on Wednesday, September 2nd. Mizuho set a $115.00 price target on Medtronic in a report on Wednesday, September 2nd. Finally, Jefferies Financial Group reissued a “hold” rating and set a $88.00 price target on shares of Medtronic in a report on Thursday, June 4th. Nineteen analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $103.92.

Read Our Latest Research Report on Medtronic

Medtronic Price Performance

Shares of Medtronic stock opened at $92.01 on Thursday. The company has a quick ratio of 1.54, a current ratio of 2.07 and a debt-to-equity ratio of 0.50. The stock has a market capitalization of $117.69 billion, a price-to-earnings ratio of 22.66, a price-to-earnings-growth ratio of 2.17 and a beta of 0.56. Medtronic PLC has a twelve month low of $73.31 and a twelve month high of $106.33. The company has a 50-day simple moving average of $87.58 and a two-hundred day simple moving average of $85.17.

Medtronic (NYSE:MDT – Get Free Report) last announced its earnings results on Tuesday, September 1st. The medical technology company reported $1.45 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.39 by $0.06. Medtronic had a net margin of 13.93% and a return on equity of 14.78%. The firm had revenue of $9.76 billion for the quarter, compared to analyst estimates of $9.55 billion. During the same quarter in the prior year, the business posted $1.26 EPS. The business’s revenue was up 13.7% compared to the same quarter last year. Medtronic has set its Q2 2027 guidance at 1.320-1.340 EPS and its FY 2027 guidance at 5.940-6.000 EPS. Analysts forecast that Medtronic PLC will post 5.96 EPS for the current year.

Medtronic Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, October 16th. Investors of record on Friday, September 25th will be given a dividend of $0.72 per share. The ex-dividend date of this dividend is Friday, September 25th. This represents a $2.88 dividend on an annualized basis and a yield of 3.1%. Medtronic’s dividend payout ratio is currently 70.94%.

Key Medtronic News

Here are the key news stories impacting Medtronic this week:

Positive Sentiment: Medtronic raised its fiscal 2027 organic revenue-growth outlook and increased the lower end of its adjusted earnings forecast after quarterly results exceeded expectations. Cardiovascular devices were the primary growth engine, while surgical products also contributed to broad-based expansion. Medtronic Raised its Outlook as Heart Devices Accelerate, But Can the Momentum Last?
Positive Sentiment: Recent results showed 13.7% year-over-year revenue growth, $9.76 billion in quarterly revenue versus a $9.55 billion consensus estimate, and adjusted EPS of $1.45 versus expectations of $1.39. The performance suggests improving demand across Medtronic’s cardiovascular and surgical franchises. Medtronic Q1 2027 Earnings Call Transcript
Positive Sentiment: Medtronic remains attractive to income-focused investors, offering a roughly 3% dividend yield and having increased its dividend for 49 consecutive years. The company is potentially two years away from reaching “Dividend King” status, which could support long-term shareholder interest. Medtronic Is on the Cusp of Becoming a Dividend King
Neutral Sentiment: Analysts view the improved growth and earnings outlook favorably, but investors remain selective because Medtronic must demonstrate that its cardiovascular acceleration is sustainable beyond the latest quarter.
Negative Sentiment: Margin pressure, foreign-exchange effects, execution risks and intense medical-device competition could limit the benefit of stronger sales growth. These concerns help explain why the stock has not fully reflected the improved outlook. Medtronic Raises 2027 Outlook as Broad-Based Growth Gains Momentum

Medtronic Profile

(Free Report)

Medtronic plc is a global medical technology company that develops, manufactures and sells devices and therapies used to diagnose and treat a broad range of medical conditions. Its products are designed for hospitals, physicians and patients across areas including cardiac care, diabetes, neurological disorders, spinal conditions and surgical procedures.

The company’s portfolio includes pacemakers, implantable cardioverter-defibrillators, cardiac ablation systems, heart valves, neurostimulation systems, implantable pumps, spinal implants and surgical technologies.